RECURRENT THYROID GLAND MEDULLARY CARCINOMA
Clinical trials for RECURRENT THYROID GLAND MEDULLARY CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT THYROID GLAND MEDULLARY CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT THYROID GLAND MEDULLARY CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can reprogrammed immune cells take on a rare thyroid cancer?
⭐️ CURE ⭐️ OngoingThis early-phase trial is testing whether a single infusion of specially engineered immune cells (called CAR T cells) can safely target and attack medullary thyroid cancer that has spread or come back. The cells are designed to recognize a protein called GFRα4 found on the cancer…
Matched conditions: RECURRENT THYROID GLAND MEDULLARY CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: RECURRENT THYROID GLAND MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: RECURRENT THYROID GLAND MEDULLARY CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC